Louis Philipson to Genetic Testing
This is a "connection" page, showing publications Louis Philipson has written about Genetic Testing.
Connection Strength
0.917
-
Who should have genetic testing for maturity-onset diabetes of the young? Clin Endocrinol (Oxf). 2011 Oct; 75(4):422-6.
Score: 0.302
-
Precision diabetes: Lessons learned from maturity-onset diabetes of the young (MODY). J Diabetes Investig. 2022 Sep; 13(9):1465-1471.
Score: 0.159
-
Approach to the Patient with MODY-Monogenic Diabetes. J Clin Endocrinol Metab. 2021 01 01; 106(1):237-250.
Score: 0.144
-
Sulfonylurea treatment before genetic testing in neonatal diabetes: pros and cons. J Clin Endocrinol Metab. 2014 Dec; 99(12):E2709-14.
Score: 0.094
-
Cost-effectiveness of MODY genetic testing: translating genomic advances into practical health applications. Diabetes Care. 2014; 37(1):202-9.
Score: 0.087
-
The cost-effectiveness of personalized genetic medicine: the case of genetic testing in neonatal diabetes. Diabetes Care. 2011 Mar; 34(3):622-7.
Score: 0.072
-
Monogenic Diabetes in Children and Adolescents: Recognition and Treatment Options. Curr Diab Rep. 2018 06 22; 18(8):58.
Score: 0.030
-
Pancreatic Histopathology of Human Monogenic Diabetes Due to Causal Variants in KCNJ11, HNF1A, GATA6, and LMNA. J Clin Endocrinol Metab. 2018 01 01; 103(1):35-45.
Score: 0.029